Chronic Kidney Disease

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Advanced CKD shows higher rates of certain ERCP complications but not post-ERCP pancreatitis compared with the general population.

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Check out renal FDA news, new KDIGO guidelines on IgAN and IgAV management, research about hypertensive kidney disease, and more.

Neuen is joined by Richard Pratley, MD, and Muthiah Vaduganathan, MD, MPH, to discuss the evolving landscape of CKM trial design.

A trio of experts and a patient advocate discuss unmet needs and recent innovations in kidney transplantation, from xenotransplantation to continuous hypothermic machine perfusion.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

The US Food and Drug Administration has approved bumetanide nasal spray for the treatment of edema in outpatient heart, liver, and kidney diseases.

Garimella describes recent progress in renal xenotransplantation, uncertainties that still need to be addressed, and how he sees it impacting the field moving forward.

The first patient in the ongoing Multi-Patient Expanded Access study has surpassed 7 months kidney function, and a second patient has been successfully transplanted.

The death rate from high blood pressure-related kidney disease increased by 48% from 1999-2023, with notable disparities by race, ethnicity, sex, and region.

Salvatore Viscomi, MD, warns CKDu is a growing global health crisis, driven by heat stress, toxins, and occupational risks in vulnerable populations.

Check out renal FDA news and new research on pediatric kidney stone management, CKD trends, spironolactone for dialysis patients, and more.